Q: What is Eli Lilly(LLY) 2024Q2 Earnings Summary?
**Bullish Points:**
1. **Revenue Growth:**
- Revenue for the quarter ended September 30, 2024, increased to $11,439.1 million from $9,498.6 million in the same period in 2023.
- Revenue for the nine months ended September 30, 2024, increased to $31,509.9 million from $24,770.7 million in the same period in 2023.
- Significant revenue increases in the cardiometabolic health segment, particularly from Mounjaro and Zepbound.
- Oncology and immunology segments also showed strong revenue growth.
2. **Net Profit:**
- Net income for the quarter ended September 30, 2024, was $970.3 million, compared to a net loss of $57.4 million in the same period in 2023.
- Net income for the nine months ended September 30, 2024, was $6,180.2 million, compared to $3,050.7 million in the same period in 2023.
3. **Comprehensive Income:**
- Comprehensive income for the quarter ended September 30, 2024, was $1,074.0 million, compared to a comprehensive loss of $53.6 million in the same period in 2023.
- Comprehensive income for the nine months ended September 30, 2024, was $6,232.4 million, compared to $3,110.4 million in the same period in 2023.
4. **Management Analysis:**
- The increase in revenue and net income is attributed to higher sales and improved operational efficiencies.
- Continued investment in research and development reflects the company's commitment to innovation.
5. **Debt Management:**
- Short-term borrowings and current maturities of long-term debt decreased significantly.
- Issued substantial long-term debt to fund acquisitions and general business purposes.
6. **Cash Flows:**
- Net cash provided by operating activities increased to $6,344.1 million for the nine months ended September 30, 2024, from $4,552.0 million in the same period in 2023.
7. **Share Repurchase and Dividends:**
- Repurchased $521.1 million of shares and paid dividends of $3.51 billion during the nine months ended September 30, 2024.
**Bearish Points:**
1. **Operating Costs:**
- Cost of sales, research and development expenses, and marketing, selling, and administrative expenses all increased for the quarter ended September 30, 2024.
- Depreciation and amortization expenses, and stock-based compensation expenses also increased.
2. **Debt Changes:**
- Long-term debt increased significantly to $29,045.4 million as of September 30, 2024, from $18,320.8 million as of December 31, 2023.
- Total debt increased to $31.12 billion as of September 30, 2024, from $25.23 billion as of December 31, 2023.
3. **Interest Expense:**
- Interest expense for the three months ended September 30, 2024, was $192.7 million, compared to $124.6 million in the same period in 2023.
- Interest expense for the nine months ended September 30, 2024, was $555.9 million, compared to $347.7 million in the same period in 2023.
4. **Foreign Currency Exchange Rates:**
- Fluctuations in foreign currency exchange rates have had and could continue to have a material impact on consolidated results of operations and cash flows.
5. **Other Factors:**
- Factors such as cost and wage inflation, supply chain and labor market complexities, international tension and conflicts, and uneven economic growth or downturns have impacted and may continue to impact consolidated results of operations.
**Summary:**
Eli Lilly (LLY) has shown strong financial performance for the quarter and nine months ended September 30, 2024, with significant increases in revenue and net income. The company has also managed to improve its comprehensive income and cash flows. However, the increase in operating costs, long-term debt, and interest expenses are areas of concern. Additionally, external factors such as foreign currency exchange rates and economic conditions could pose risks. Overall, the company's strong revenue growth and strategic investments in research and development position it well for future growth, but it must manage its rising costs and debt levels carefully.
For more information, you can read the original text of [Eli Lilly's financial report](https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/lly-20240930.htm).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
